Biogen Inc. (NASDAQ:BIIB) Q2 2019 Results Earnings Conference Call July 23, 2019 8:00 AM ET
Company Participants
Michel Vounatsos - Chief Executive Officer
Joe Mara - Vice President and Head of Investor Relations
Michael Ehlers - Executive Vice President, Research & Development
Jeffrey Capello - Chief Financial Officer and Executive Vice President
Al Sandrock - Chief Medical Officer
Conference Call Participants
Cory Kasimov - JPMorgan
Terence Flynn - Goldman Sachs
Umer Raffat - Evercore
Geoffrey Porges - SVB Leerink
Michael Yee - Jefferies
Ronny Gal - Bernstein
Phil Nadeau - Cowen and Company
Matthew Harrison - Morgan Stanley
Salim Syed - Mizuho
Brian Abrahams - RBC Capital Markets
Paul Matteis - Stifel
Evan Seigerman - Crédit Suisse
Carter Gould - UBS
Mohit Bansal - Citigroup
Operator
Good morning. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Second Quarter 2019 Financial Results and Business Update. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks, there will be a question-and-answer session. [Operator Instructions] Please limit yourself to one question to allow other participants time for questions. [Operator Instructions] Thank you.
I would now like to turn the conference over to Biogen CEO, Michel Vounatsos. You may begin your conference.
Michel Vounatsos
Thank you. Good morning, everyone and thank you for joining us. I would like to start by thanking Matt Calistri for nearly four years he spent leading our Investor Relations program. We wish him the very best in this next endeavor.
I would like to welcome Joe Mara, our new Vice President and Head of Investor Relations, who is a talented and energized finance and business leader with over 12 years of experience at Biogen across a number of functions. I am confident that Joe will prove to be a valuable resource for the investment community and I look forward to all of you getting to know Joe.
Joe the floor is yours. Welcome.
Joe Mara
Thank you, Michelle. And welcome everyone to Biogen's second quarter 2019 earnings conference call. I look forward to getting to know all of you over the coming months.
Before I begin, I encourage everyone to go to the Investors section of biogen.com to find the earnings release and related financial tables, including a reconciliation of the GAAP to non-GAAP financial measures that we will discuss today. Our GAAP financials are provided in tables one and two and table three includes a reconciliation of our GAAP to non-GAAP financial results. We believe non-GAAP financial results better represent the ongoing economics of our business and reflect how we manage the business internally. We've also posted slides on our website that follow the discussions related to this call.
I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.
On today's call I am joined by our Chief Executive Officer, Michel Vounatsos; Dr. Michael Ehlers, EVP of the Research and Development; and our CFO, Jeff Capello. We will also be joined for the Q&A portion of the call by our Chief Medical Officer, Dr. Al Sandrock.
Now, I will turn the call back over to Michel.
